Ever since last year’s annual American Association of Cancer Research (AACR) meeting, Volastra’s phone has been “ringing off the hook,” according to CEO Charles Hugh-Jones, M.D. | Two years since its inception, Volastra Therapeutics is partnering with Bristol Myers Squibb for up to three oncology targets focused on chromosomal instability, a deal that could exceed $1.1 billion should the assets hit milestones.